{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 49,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/33",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.1,
        "x": 0.42,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Best % Change from Baseline in Size of Target Lesions",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79d0de8c-8e42-434e-9841-7c1f3cc8caa8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Soft Tissue Sarcoma | iMX-110 Monotherapy line chart",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ec6612a-07f7-4ee0-8ead-b680768f7fde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.58,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Non-Sarcoma Cancers | iMX-110 Monotherapy line chart",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff1451e1-7bf2-461d-b0f8-6d41e180ec63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Immix Biopharma, Inc. ImmixBio has evaluable data for the 8 patients as of October 2021...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3197ae5f-b0d1-41d8-806d-35814902959e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "IMX-110 1b/2a Data: Tumor Shrinkage in 75% of Heavily Pretreated Soft Tissue Sarcoma Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fa8a124-7bc3-4308-a903-d5c319a60da5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "9f9e59ed-7018-46e0-91d5-84705bcf69ca",
      "evidence": "chart/bar-vertical: Best % Change from Baseline in Size of Target Lesions",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 36,
      "from": 22,
      "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Discussion of market opportunity and clinical development plan",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 22,
      "name": "Pareto Focus",
      "slug": "50-pareto-focus",
      "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
      "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
      "evidence": "Presentation of market data and clinical development plan",
      "position": 1,
      "objective": "Focusing on key markets and opportunities",
      "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
      "confidence": 0.7,
      "description": "Show that 80% of results come from 20% of causes to drive prioritization"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}